Research & Development

Biozenta gives prime importance to R&D as its one of the major belief and success factor and making its vision and mission alive. Biozenta R&D division focuses on the development of new products across wide range of therapies including Oncology, Anti-cancer, Cytotoxic, Critical-care, Life-saving, General Injectables, Contrast Media Injectables, Oral Solids - Tablets and Capsules – including Ant-retrovirals (ARVs), External Preparations – Derma and Cosmetics and also Oncology Active Pharmaceutical Ingredients (API’s).

Biozenta has R&D strengths in developing intellectual property in non-infringing processes and solving complex chemistry challenges. Biozenta is in the process of developing new drug delivery systems, new dosage formulations and implementing new technology for improved processes.

The R&D centre at UNA, H.P., provides a nurturing environment to a multi-disciplinary team of its scientists striving for excellence. RandD centre meets cGLP requirements, and focuses on the areas of organic synthesis, analytical research, dosage development, pharmacology, bio-equivalent studies and drug delivery systems.

The tools and analytical knowledge base at the R&D centre facilitate:

• Complete impurity profiling in all products developed.
• Development of analytical methods and specifications from raw materials to non-supplementary finished products.
• In-house synthesis of reagents for the analysis of lithium and noble metals.
• Quick and real time stability study.
• This reflects the company's commitment towards developing innovative technologies and building a knowledge base in chemical synthesis, high quality generic formulations and drug delivery system development.

Our strength

Excellent R&D infrastructure

Biozenta’s R&D centre is well-equipped to deal with various developmental challenges in the areas of oral and parenteral drugs. Specifically, the available infrastructure includes:

• Dedicated areas and laboratories for handling potent substances such as hormones.
• Process development and scale-up labs attached to the manufacturing unit.
• An NDDS laboratory with specialized capabilities like nano-technology, etc.
• A unit for developing parenteral dosage forms from vials to ampoules to pre-filled syringes to parenteral in large quantities.
• A unit for developing Ophthalmic and Nasal products using BFS technology.
• Supporting dedicated packaging development laboratories with multifeeder BQS machinery capable of various packs including multi-product-in-a-blister.
• Dedicated analytical laboratories with UPLC, ion chromatography, an amino acid analyser, particle size and particle surface area analysers, hot phase microscopy, USP Type III and Type IV instruments etc.